Active Not Recruiting PHASE1 INTERVENTIONAL 3-arm NCT05552469

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases

Sponsor: Novartis Pharmaceuticals

Conditions Myeloid Diseases

Interventions DFV890

Updated 23 times since 2022 Last updated: Mar 9, 2026 Started: May 8, 2023 Primary completion: Jan 29, 2027 Completion: Feb 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Myeloid Diseases and is currently ongoing. Novartis Pharmaceuticals leads this study, which shows 23 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

23 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE1
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Dec 2025 — Feb 2026 [monthly]

Recruiting PHASE1
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE1
Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE1

▶ Show 18 earlier versions

Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1
Jun 2025 — Sep 2025 [monthly]

Recruiting PHASE1
Apr 2025 — Jun 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Oct 2023 — Dec 2023 [monthly]

Recruiting PHASE1
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1
Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE1
May 2023 — Jun 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Dec 2022 — May 2023 [monthly]

Not Yet Recruiting PHASE1
Nov 2022 — Dec 2022 [monthly]

Not Yet Recruiting PHASE1
Sep 2022 — Nov 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Boston, United States , Brescia, Italy , Cardiff, United Kingdom , Chicago, United States , Dresden, Germany , Düsseldorf, Germany , Grenoble, France , Hong Kong, Hong Kong , Houston, United States and 15 more locations